CLINICAL STUDY: CARDIOMYOPATHY
Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial
Gennaro Cice, MD*,
Luigi Ferrara, MD*,
Attilio Di Benedetto, MD ,
Pina Elvira Russo, MD*,
Giancarlo Marinelli, MD*,
Francesco Pavese, MD* and
Aldo Iacono, MD, FESC*
* Institute of Cardiovascular Clinic and Surgery, Division of Cardiology, Second University of Naples, Naples, Italy
Total Renal Care, Italia-Study Group on Cardiovascular Risk in Uremic Patients, Naples, Italy
Manuscript received May 10, 2000;
revised manuscript received September 15, 2000,
accepted October 26, 2000.
Reprint requests and correspondence: Dr. Gennaro Cice, Second University of Naples, Institute of Cardiovascular Clinic and Surgery, Division of Cardiology, Piazza L, Miraglia, 2-80138 Napoli, Italy
lugife{at}tin.it
OBJECTIVES
The aim of this study was to investigate in dialysis patients with symptomatic heart failure New York Heart Association (NYHA) functional class II or III whether the addition of carvedilol to conventional therapy is associated with beneficial effects on cardiac architecture, function and clinical status.
BACKGROUND
Congestive heart failure (CHF) in chronic hemodialyzed patients, particularly when associated with dilated cardiomyopathy, represents an ominous complication and is an independent risk factor for cardiac mortality.
METHODS
We enrolled 114 dialysis patients with dilated cardiomyopathy. All patients were treated with carvedilol for 12 months in a double-blind, placebo-controlled, randomized trial. The patients underwent M-mode and two-dimensional echocardiography at baseline, 1, 6 and 12 months after the randomization. Each patient’s clinical status was assessed using an NYHA functional classification that was determined after 6 and 12 months of treatment.
RESULTS
Carvedilol treatment improved left ventricular (LV) function. In the active-treatment group, the increase in LV ejection fraction (from 26.3% to 34.8%, p < 0.05 vs. basal and placebo group) and the reduction of both LV end-diastolic volume (from 100 ml/m2 to 94 ml/m2, p < 0.05 vs. basal and placebo group) and end-systolic volume (from 74 ml/m2 to 62 ml/m2, p < 0.05 vs. basal and placebo group) reached statistical significance after six months of therapy, compared with baseline and corresponding placebo values, and they remained constant at one year of treatment (p < 0.05 vs. basal and placebo group). The clinical status of patients, assessed by NYHA functional classification, improved during the treatment period. Moreover, at the end of the trial, there were no patients in NYHA functional class IV in the carvedilol group, compared with 5.9% of the patients in the placebo arm.
CONCLUSIONS
One year of therapy with carvedilol in dialysis patients with CHF and dilated cardiomyopathy reduces LV volumes and improves LV function and clinical status.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | BP | = blood pressure | | CHF | = congestive heart failure | | HR | = heart rate | | LV | = left ventricle, left ventricular | | LVEDV | = left ventricular end-diastolic volume | | LVEF | = left ventricular ejection fraction | | LVESV | = left ventricular end-systolic volume | | MI | = myocardial infarction | | NYHA | = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
A. Cohen-Solal, D. Kotecha, D. J van Veldhuisen, D. Babalis, M. Bohm, A. J. Coats, M. Roughton, P. Poole-Wilson, L. Tavazzi, M. Flather, et al.
Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
Eur J Heart Fail,
September 1, 2009;
11(9):
872 - 880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Bleyer
CLUES AT THE SCENE OF THE CRIME: SUDDEN DEATH IN DIALYSIS PATIENTS
Perit. Dial. Int.,
January 1, 2009;
29(1):
23 - 25.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Banerjee, J. Z. Ma, A. J. Collins, and C. A. Herzog
Long-Term Survival of Incident Hemodialysis Patients Who Are Hospitalized for Congestive Heart Failure, Pulmonary Edema, or Fluid Overload
Clin. J. Am. Soc. Nephrol.,
November 1, 2007;
2(6):
1186 - 1190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Tripepi, F. A. Benedetto, F. Mallamaci, R. Tripepi, L. Malatino, and C. Zoccali
Left Atrial Volume Monitoring and Cardiovascular Risk in Patients with End-Stage Renal Disease: A Prospective Cohort Study
J. Am. Soc. Nephrol.,
April 1, 2007;
18(4):
1316 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Abdulla, L. Kober, E. Christensen, and C. Torp-Pedersen
Effect of beta-blocker therapy on functional status in patients with heart failure -- A meta-analysis
Eur J Heart Fail,
August 1, 2006;
8(5):
522 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Berl and W. Henrich
Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment
Clin. J. Am. Soc. Nephrol.,
January 1, 2006;
1(1):
8 - 18.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. McBride and C. M. White
Critical Differences Among Beta-Adrenoreceptor Antagonists in Myocardial Failure: Debating the MERIT of COMET
J. Clin. Pharmacol.,
January 1, 2005;
45(1):
6 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dikow and E. Ritz
Cardiovascular complications in the diabetic patient with renal disease: an update in 2003
Nephrol. Dial. Transplant.,
October 1, 2003;
18(10):
1993 - 1998.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Herzog
How to Manage the Renal Patient with Coronary Heart Disease: The Agony and the Ecstasy of Opinion-Based Medicine
J. Am. Soc. Nephrol.,
October 1, 2003;
14(10):
2556 - 2572.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cice, L. Ferrara, A. D'Andrea, S. D'Isa, A. Di Benedetto, A. Cittadini, P. E. Russo, P. Golino, and R. Calabro
Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial
J. Am. Coll. Cardiol.,
May 7, 2003;
41(9):
1438 - 1444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Amann, C. Ritz, M. Adamczak, and E. Ritz
Why is coronary heart disease of uraemic patients so frequent and so devastating?
Nephrol. Dial. Transplant.,
April 1, 2003;
18(4):
631 - 640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A Sica and T. W. Gehr
Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
Journal of Renin-Angiotensin-Aldosterone System,
December 1, 2002;
3(4):
247 - 254.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Chan, J. S. Floras, J. A. Miller, and A. Pierratos
Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure
Nephrol. Dial. Transplant.,
August 1, 2002;
17(8):
1518 - 1521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Carvedilol for Dilated Cardiomyopathy in Dialysis Patients
Journal Watch (General),
March 20, 2001;
2001(320):
4 - 4.
[Full Text]
|
|
|
|
